Related Experiment Video
Updated: Mar 9, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy
Jintong Chen1, Yinghua Zhao1, Xiao Chu1
1Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University , Changchun, China.
Abstract:
Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cells in vivo. Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.
Related Concept Videos
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

